---
title: Phase 3 Trial of Selpercatinib in Advanced <em>RET</em>-Mutant Medullary Thyroid
  Cancer
date: '2023-10-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37870969/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20231024180819&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: Selpercatinib treatment resulted in superior progression-free
  survival and treatment failure-free survival as compared with cabozantinib or vandetanib
  in patients with RET-mutant medullary thyroid cancer. (Funded by Loxo Oncology,
  a subsidiary of Eli Lilly; LIBRETTO-531 ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Selpercatinib treatment resulted in superior progression-free survival and treatment failure-free survival as compared with cabozantinib or vandetanib in patients with RET-mutant medullary thyroid cancer. (Funded by Loxo Oncology, a subsidiary of Eli Lilly; LIBRETTO-531 ClinicalTrials.gov number, ...